MAPT and Alzheimer disease: Another in vivo evaluation was conducted by Mormino et al., which underwent an 18F-PI-2620 tau PET scan on six healthy subjects, 11 beta-amyloid positive patients with cognitive impairment (with a clinical diagnosis of AD or mild cognitive impairment), and two humans with semantic variant primary progressive aphasia (svPPA) [60].